Recent

% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • swank818 swank818 Feb 12, 2013 3:05 AM Flag

    Shame that Roche is trashing Herceptin Subcu...One less possible revenue source

    They went out of their way to really ditch that whole vein in the last cc. When a company has 6 or 8 items that are supposed to create future royalties and revenue streams and one of the biggies gets torpedoed, that ain't good!! (in case you can't tell by the share price!) Yes, they were giving out tons of free stock and then stock options...Freebies for everyone.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • as we speak 3 companies making generic Herceptin thus l think Roche simply throwing them a curve...alternatively maybe Roche a little #$%$ re Ph deal with Halo and teaching Frost a lesson....Herceptin has major sales look at R numbers

      Sentiment: Strong Buy

      • 1 Reply to vic7777r
      • soho_riots@rocketmail.com soho_riots Feb 22, 2013 9:30 AM Flag

        Roche has said that generics won't be available until at least 2016. And the vengeful Roche theory is just ridiculous. Herceptin is a blockbuster, but not all of those sales will be up for grabs. A little under $6 billion total. Take out the U.S. - $2.8 billion. The vast majority of Herceptin patients are using it in the adjuvant setting for 1 year. The first 3 months it is used in conjunction with chemotherapy, so most will probably just take it as another infusion during this period - $2 billion. If you get 50% of the market (which will take some time) that gives you around $1 billion. If HALO's royalty is 5%, that is $50 million. If HALO's royalty is 3% (like, I believe, IMGN's royalty is) then you are at $30 million. Maybe $10-15 million the first year. TDM-1 will take a growing percentage of that over the next few years, until it completely replaces Herceptin. Subcu Herceptin feels like a Plan B, in case TDM-1 failed; a scenario that appears less and less likely. The same could be said about subcu MabThera and GA101. Anyone else have thoughts on sales projections?

    • I don't think that Herceptin was critical to their future. Let's see what they say on the cc coming up.

 
HALO
9.82+0.27(+2.83%)Aug 26 4:00 PMEDT